AI Summary & Key Takeaways
AI InsightDriver mutations were more common in females and in non-smoking patients.
📌 3 Key Takeaways
Özet
Objectives: Driver mutations are detected in 30–35% of metastatic non-small cell lung cancer (NSCLC) patients, and mutation discordance may occur between biopsies. Therefore, false negative results for a driver mutation are reported in some patients who may need rebiopsy. We aim to determine a clinicopathological feature (especially tumor localization), other than smoking and gender, that predicts driver mutation in metastatic non-squamous NSCLC. Methods: A total of 75 patients with driver mutation reports were included in the study. The age, gender, smoking status, pathology, primary tumor location, and mutation of each patient were evaluated. The relationship between the clinicopathological features and driver mutations was analyzed. Results: The median age of the patients was 66 (range: 36–85); 55 (73%) of the patients were male. A driver mutation was detected in 23 (30.7%) patients. The rates of EGFR, ALK, and ROS1 were 22.7%, 6.7%, and 1.3%, respectively. Driver mutations were more commonly found in females and non-smokers (the p-values were 0.029 and <0.001, respectively). Driver mutation rates were similar in the right and left lungs (p=0.504). Conclusion: There was no relationship between primary tumor localization and driver mutations. Driver mutations were more common in females and in non-smoking patients.